Allogene Therapeutics Inc
NASDAQ:ALLO

Watchlist Manager
Allogene Therapeutics Inc Logo
Allogene Therapeutics Inc
NASDAQ:ALLO
Watchlist
Price: 2.54 USD -6.62% Market Closed
Market Cap: 531.1m USD
Have any thoughts about
Allogene Therapeutics Inc?
Write Note

Allogene Therapeutics Inc
Selling, General & Administrative

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Allogene Therapeutics Inc
Selling, General & Administrative Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Selling, General & Administrative Analysis
Latest Figures & CAGR of Competitors

Company Selling, General & Administrative CAGR 3Y CAGR 5Y CAGR 10Y
Allogene Therapeutics Inc
NASDAQ:ALLO
Selling, General & Administrative
-$121.4m
CAGR 3-Years
-19%
CAGR 5-Years
-17%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Selling, General & Administrative
-$14B
CAGR 3-Years
-5%
CAGR 5-Years
-15%
CAGR 10-Years
-9%
Gilead Sciences Inc
NASDAQ:GILD
Selling, General & Administrative
-$5.6B
CAGR 3-Years
-2%
CAGR 5-Years
-6%
CAGR 10-Years
-8%
Amgen Inc
NASDAQ:AMGN
Selling, General & Administrative
-$7.5B
CAGR 3-Years
-9%
CAGR 5-Years
-8%
CAGR 10-Years
-5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Selling, General & Administrative
-$1.5B
CAGR 3-Years
-22%
CAGR 5-Years
-19%
CAGR 10-Years
-17%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Selling, General & Administrative
-$2.9B
CAGR 3-Years
-23%
CAGR 5-Years
-16%
CAGR 10-Years
-21%

See Also

What is Allogene Therapeutics Inc's Selling, General & Administrative?
Selling, General & Administrative
-121.4m USD

Based on the financial report for Sep 30, 2024, Allogene Therapeutics Inc's Selling, General & Administrative amounts to -121.4m USD.

What is Allogene Therapeutics Inc's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 5Y
-17%

Over the last year, the Selling, General & Administrative growth was -61%. The average annual Selling, General & Administrative growth rates for Allogene Therapeutics Inc have been -19% over the past three years , -17% over the past five years .

Back to Top